C4 Therapeutics (CCCC) Invested Capital (2019 - 2025)
Historic Invested Capital for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $154.4 million.
- C4 Therapeutics' Invested Capital fell 3636.75% to $154.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $154.4 million, marking a year-over-year decrease of 3636.75%. This contributed to the annual value of $216.0 million for FY2024, which is 1224.15% down from last year.
- Per C4 Therapeutics' latest filing, its Invested Capital stood at $154.4 million for Q3 2025, which was down 3636.75% from $174.1 million recorded in Q2 2025.
- C4 Therapeutics' 5-year Invested Capital high stood at $416.4 million for Q2 2021, and its period low was $154.4 million during Q3 2025.
- In the last 5 years, C4 Therapeutics' Invested Capital had a median value of $258.3 million in 2024 and averaged $278.3 million.
- Per our database at Business Quant, C4 Therapeutics' Invested Capital skyrocketed by 40831.6% in 2021 and then tumbled by 3636.75% in 2025.
- Over the past 5 years, C4 Therapeutics' Invested Capital (Quarter) stood at $389.6 million in 2021, then fell by 22.82% to $300.7 million in 2022, then decreased by 18.16% to $246.1 million in 2023, then dropped by 12.24% to $216.0 million in 2024, then dropped by 28.51% to $154.4 million in 2025.
- Its Invested Capital was $154.4 million in Q3 2025, compared to $174.1 million in Q2 2025 and $195.1 million in Q1 2025.